Primary Sjogren's syndrome
Conditions
Brief summary
Proportion of patients achieving a response according to preliminary STAR at week 24 between each active treatment arm and placebo arm. • Cohort 2: Proportion of patients achieving a response according to preliminary STAR at week 24 between each active treatment arm and placebo arm.
Interventions
DRUGPlacebo of leflunomide
DRUGMycophenolate mofetil Teva 500 mg film-coated tablets
DRUGPLAQUENIL 200 mg
DRUGcomprimé pelliculé
Sponsors
Assistance Publique Hopitaux De Paris
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving a response according to preliminary STAR at week 24 between each active treatment arm and placebo arm. • Cohort 2: Proportion of patients achieving a response according to preliminary STAR at week 24 between each active treatment arm and placebo arm. | — |
Countries
France, Greece, Italy, Netherlands, Norway, Spain, Sweden
Outcome results
None listed